Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies

The authors investigate how Mezigdomide, an immunomodulatory drug, can reduce T cell dysfunction in multiple myeloma (MM) patients and enhance the efficacy of anti-myeloma therapies. They find that Mezigdomide decreases populations of dysfunctional T cells by targeting the transcription factor Ikaros, which regulates exhaustion markers like TIGIT, ultimately improving T cell function and survival outcomes in CAR-T therapy. This study highlights the potential of Mezigdomide to improve treatment responses in MM by mitigating T cell exhaustion.